Drs. Geoffrey Oxnard and Lauren Ritterhouse consider the current landscape of reimbursement for molecular biomarker testing, the need to run FDA-approved tests, and the role of CMS and local Medicare providers in testing reimbursement.
Please submit your manuscripts using the form below. Papers submitted to our journal usually have a first decision within 4-6 weeks. If you have any questions, please contact the Editorial Director at firstname.lastname@example.org.